Objectives: Several randomized controlled trials have compared adrenaline (epinephrine) with alternative therapies in patients with cardiac arrest with conflicting results. Recent observational studies suggest that adrenaline might increase return of spontaneous circulation but worsen neurologic outcome. We systematically compared all the vasopressors tested in randomized controlled trials in adult cardiac arrest patients in order to identify the treatment associated with the highest rate of return of spontaneous circulation, survival, and good neurologic outcome. Design: Network meta-analysis. Patients: Adult patients undergoing cardiopulmonary resuscitation. Interventions: PubMed, Embase, BioMed Central, and the Cochrane Central register were searched (up to April 1, 2017). We included all the randomized controlled trials comparing a vasopressor with any other therapy. A network meta-analysis with a frequentist approach was performed to identify the treatment associated with the highest likelihood of survival.
C ardiac arrest is the most severe medical emergency; despite wide efforts to improve outcome, only a minority of resuscitated patients is discharged in good neurologic condition.
Out-of-hospital cardiac arrest (OHCA) has an estimated occurrence rate of 55-113 cases yearly per 100,000 inhabitants with crude survival rates ranging from 6% to 22% (1) (2) (3) (4) (5) . In-hospital cardiac arrest (IHCA) has a reported occurrence rate of one to five cases every 1,000 patients (6) (7) (8) , with survival rates of approximately 24% (9) .
Current guidelines on cardiopulmonary resuscitation (CPR) and advanced life support (ALS) recommend the administration of 1 mg of adrenaline (epinephrine) via IV or intraosseous route every 3-5 minutes during resuscitation; however, this recommendation is based on expert opinion, and there is no direct evidence that adrenaline increases survival to hospital discharge (10) . In addition, recent observational studies suggest that administration of adrenaline may increase the rate of return of spontaneous circulation (ROSC) but at the cost of a worse neurologic outcome in survivors (11) .
Several randomized controlled trials (RCTs) have compared standard adrenaline with higher doses of adrenaline, alternative vasopressors (e.g., vasopressin), combinations of vasopressors, or placebo (12) (13) (14) (15) (16) (17) , with conflicting results. However, results of these trials have not been compared with each other in order to detect which pharmacologic strategy is the best (18) .
A network meta-analysis (NMA) is a statistical technique that allows performing an indirect comparison between treatments that have never been directly compared in randomized clinical trials (19) (20) (21) .
Therefore, we performed a NMA to indirectly compare and grade all the vasopressor drugs tested in RCTs in adult patients with cardiac arrest in order to identify the treatment associated with the highest survival rate, the highest likelihood of ROSC, and the best neurologic outcome.
MATERIALS AND METHODS
We performed a systematic review and NMA according to the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) statement (PRISMA-NMA; checklist is available in Supplemental Digital Content 1, http://links.lww. com/CCM/D314) (22) (23) (24) (25) .
Data Sources and Search Strategy
Relevant studies were searched on PubMed, Embase, BioMed Central, and the Cochrane Central register by two independent investigators. Our search strategy aimed to include every RCT investigating the use of a vasopressor agent in adult patients with cardiac arrest. In addition, we employed backward snowballing (i.e., scanning of references of retrieved articles and pertinent reviews) to identify further studies. Literature search was last updated April 1, 2017. The PubMed search strategy, modified from Biondi-Zoccai et al (26) , is available in the supplementary appendix (Supplemental Digital Content 2, http://links.lww.com/CCM/D315).
Study Selection
Two investigators first examined references at a title/abstract level, and then, if potentially pertinent, retrieved the complete articles. All RCTs on adult patients in cardiac arrest, with at least one group randomized to receive a vasopressor, were considered for inclusion. Exclusion criteria were nonadult population, overlapping population, lack of mortality data, study published as abstract only, and study investigating drugs not available on the market.
Data Extraction and Quality Assessment
Cardiac arrest setting, presentation rhythm, procedural, outcome, and follow-up data were independently abstracted by two investigators. Patients randomized to placebo and those randomized to standard treatment were aggregated together as a single comparison group. After extraction of procedural data from studies comparing low-dose versus high-dose adrenaline (13, (27) (28) (29) (30) (31) (32) (33) (34) , we decided to define low-and highdose adrenaline as follows: low-dose adrenaline was less than or equal to 1 mg or 0.02 mg/kg (1.4 mg in a 70 kg person) and high-dose adrenaline was greater than or equal to 2 mg or 0.1 mg/kg. This definition is consistent with results of animal trials performed in the late 80s and early 90s suggesting that adrenaline doses higher than 1 mg might results in improved outcome (35) (36) (37) (38) (39) (40) . Two independent investigators assessed the internal validity and risk of bias (at a study level) of included trials according to the "Risk of bias assessment tool" developed by The Cochrane collaboration (41) , with divergences resolved by consensus.
Data Synthesis and Analysis
Primary outcome was survival at the longest follow-up available, whereas secondary outcomes were ROSC rate and survival with a good neurologic outcome at the longest follow-up available. Good neurologic outcome was defined as per Authors' definition in each study (detailed in Table 1 ). Subgroup analyses included patients with IHCA versus OHCA and patients with shockable versus nonshockable presentation rhythms.
Dichotomous variables were reported as percentages, whereas continuous variables were reported as mean ± sd or median (interquartile range). NMA with a frequentist approach was used to compare mortality at the longest follow-up available between different therapies using the netmeta R package version 8.0 (available at: http://CRAN.Rproject.org/package=netmeta) to calculate point estimates of risk differences (RDs) with 95% CIs and generate headto-head comparison and forest plots using fixed-effects (in case of low heterogeneity/inconsistency) and random-effects models (in case of high heterogeneity/inconsistency) comparing the effect estimates of different therapies relative to low-dose adrenaline (21) . P rank scores were generated to determine probability scores to rank which therapies result in the highest survival. Heterogeneity and inconsistency were assessed to generate heat plots, these are a matrix visualization proposed by Krahn et al (56) that highlight hot spots of inconsistency between specific direct evidence in the whole network and allows to highlight possible drivers. Data were analyzed according to the intention-to-treat principle whenever possible. Statistical analysis was performed using R (21, (57) (58) (59) (60) , with statistical significance for hypothesis testing set at the 0.05 two-tailed level and for heterogeneity testing at the 0.10 two-tailed level.
RESULTS

Study Characteristics
The literature search yielded a total of 372 studies. Of these, 325 were excluded at the title or abstract level because not relevant to the study question or clearly meeting the exclusion criteria (e.g. nonrandomized studies, studies performed in setting other than cardiac arrest, animal studies). A total of 19 studies were then excluded due to prespecified criteria (Supplementary Brown et al (27) Low-dose adrenaline vs high-dose adrenaline included in the final analysis (flow-chart for trial inclusion is described in Fig. 1 ) (12-17, 27-34, 42-55) . The characteristics of included trials are described in Supplementary Tables 2 and 3 (Supplemental Digital Content 2, http://links.lww.com/ CCM/D315). Twenty-six of 28 the included studies randomized patients into two treatment groups, whereas two studies randomized patients into three treatment groups (28, 43) . Thereby, a total of 58 treatment arms were analyzed. The most frequently investigated comparators were low-dose adrenaline (7,211 patients in 26 treatment arms), high-dose adrenaline (3,328 patients in 10 treatment arms), a combination of adrenaline plus vasopressin (1,673 patients in four treatment arms), and a combination treatment of adrenaline, vasopressin, and methylprednisolone (206 patients in two treatment arms). The complete list of treatment arms is reported in Supplementary Tables 2 and 3 (Supplemental Digital Content 2, http:// links.lww.com/CCM/D315). Network configuration is presented in Figure 2 .
Seven studies were judged to be at low risk of bias (12, 16, 31, 42, 47, 48, 53) , 10 studies at unclear risk of bias (13, 
Quantitative Data Synthesis
Overall Survival. Among the 12 treatments analyzed, the combination of adrenaline, vasopressin and methylprednisolone (16, 41) was associated with increased likelihood of survival as compared with low-dose adrenaline (RD vs low-dose adrenaline, 0.06; 95% CI, 0.01-0.11) (Supplementary Table 5 lww.com/CCM/D315). Rank analysis showed that this combination had the highest probability to be the best treatment in terms of survival, followed by noradrenaline (norepinephrine), vasopressin, phenylephrine and low-dose adrenaline ( Table 2) .
Network head-to-head comparison showed that the combination of adrenaline, vasopressin and methylprednisolone (16, 41) was associated with an increased survival when compared also to high-dose adrenaline, vasopressin, the combination of adrenaline-vasopressin, methoxamine, and placebo (Supplementary Table 5 ROSC. Rank analysis showed that adrenaline-vasopressinmethylprednisolone had the highest probability to be the best and Supplementary Fig. 6 , Supplemental Digital Content 2, http://links.lww.com/CCM/D315). Heterogeneity among studies was low (tau 2 < 0.0001; I 2 = 0%; Q statistics p = 0.50). Considering IHCA, the combination of adrenaline, vasopressin, and methylprednisolone was associated with increased survival compared with low-dose adrenaline (RD, 0.06; 95% CI, 0.01-0.11). Head-to-head comparison showed increased survival associated with adrenaline-vasopressin-methylprednisolone treatment when compared with high-dose adrenaline (RD, 0.07; 95% CI, 0.01-0.14) (Supplementary Tables 11  and 16 , Supplemental Digital Content 2, http://links.lww. com/CCM/D315; and Supplementary Fig. 7 
DISCUSSION
In this large NMA of randomized trials investigating vasopressors during CPR, we found that only a combined treatment with adrenaline, vasopressin, and methylprednisolone (16, 48) was associated with a significantly higher likelihood of ROSC, survival, and good neurologic outcome compared with low-dose adrenaline and to several other comparators. Conversely, methoxamine, an α 1 -adrenergic agonist (61), was associated with reduced likelihood of ROSC. Considering IHCA, the combined treatment with adrenaline, vasopressin, and methylprednisolone was once again the only treatment associated with increased survival; on the other hand, in OHCA, no treatment was found to be superior over the others. Compared with previous systematic reviews and meta-analyses published on the topic (62) (63) (64) (65) (66) (67) , this is the first study to compare and grade using a statistical analysis of the efficacy of all vasopressors tested during CPR in RCTs. In contrast, previous meta-analyses focused on single agents, usually adrenaline (63, 65, 66) or vasopressin (64, 67) . The most comprehensive systematic (but not quantitative) review published so far by Larabee et al [62] in 2012 concluded that 1) adrenaline (both a low-dose and high-dose) provide a short-term benefit in terms of ROSC, 2) there are insufficient evidences to support or discourage vasopressin use, and 3) noradrenaline may provide superior results in terms of ROSC compared with adrenaline. Treatments with highest ranking have the highest probability to be the best in terms of survival.
A major difference with our study is that Larabee et al (62) did not perform a statistical analysis of their results. The most widely investigated alternative to adrenaline has been vasopressin. Current evidence concerning vasopressin use in cardiac arrest shows no survival benefit in unselected patients. A meta-analysis by Mentzelopoulos et al (67) published in 2012 showed that vasopressin versus control was associated with higher long-term survival only in patients with asystole, especially when the drug was administered within 20 minutes from arrest. In 2014, a meta-analysis from Layek et al (64) showed that vasopressin was associated with an increased likelihood of ROSC when the drug was used in the setting of IHCA and an increased likelihood of survival to hospital discharge and survival with a favorable neurologic outcome when vasopressin was administered as "repeated boluses of 4-5 times titrated to the desired effects." We found no significant increase in the rate of ROSC or survival to the longest follow-up available when vasopressin was used compared with other agents. The most likely explanation for these differences is that results of the meta-analysis by Layek et al (64) are significantly influenced by the two studies performed by Mentzelopoulos et al (16, 48) , which were analyzed together with studies on vasopressin. In contrast, in our study, we grouped these two RCTs separately since the administration of vasopressin was combined to adrenaline and methylprednisolone, and the study design also included a postresuscitation treatment.
In their meta-analysis of RCTs and observational trials on adrenaline use during CPR, Patanwala et al (65) found that adrenaline was associated with decreased survival after cardiac arrest. However, their analysis included observational studies, subjected to higher risk of bias than RCTs, that mainly influenced the results. Differently from that study, we included only RCTs.
In our study, we were able to identify a treatment that, compared with all other vasopressors administered during CPR ever tested in RCTs, was shown to increase survival with a good neurologic outcome. Differently from previous literature, our results are for the first time supported by a statistical approach indirectly comparing the efficacy of all treatments ever assessed in RCTs. However, we acknowledge that these results are mainly driven by two studies by Mentzelopoulos et al (16) , which were performed in the setting of IHCA, with a relevant proportion of patients being already in an ICU, where all equipment for ALS and postresuscitation care are readily available, and the staff is well trained in the management of cardiac arrest. Another possible explanation for the positive results obtained by Mentzelopoulos et al (16) is the effect of steroids on postresuscitation syndrome. Steroids administration could attenuate postarrest systemic inflammatory response syndrome (68, 69) . In addition, release of adrenal hormone is frequently impaired after cardiac arrest, which reduces the physiologic stress response (70, 71) . Finally, steroids may increase response to vasopressors due to their effect on intracellular signaling pathways (72) . Notably, the protocol investigated by Mentzelopoulos et al (16) does not allow to distinguish between effects of steroids administration during versus after CPR, as patients in the treatment groups received steroids in both phases. Nevertheless, a recent multicenter RCT enrolling patients with refractory shock following cardiac arrest showed no difference in terms of shock reversal, good neurologic outcome, or survival to discharge between patients receiving hydrocortisone or placebo (73) . These results suggest that the positive effects found by Mentzelopoulos et al (16) may derive from vasopressin and methylprednisolone administration during CPR, rather than hydrocortisone administration after resuscitation.
Current ALS guidelines recommend administration of 1 mg adrenaline during CPR (10) . This recommendation is based on low quality of evidence, in particular on old, nonrandomized trials, and has been part of resuscitation guidelines for decades (74) . Although in our study we found that only adrenalinevasopressin-methylprednisolone combination was associated with increased survival, results of ranking analysis provide some interesting clues. Low-dose adrenaline was ranked only fifth, behind adrenaline-vasopressin-methylprednisolone, noradrenaline, and phenylephrine, whereas the combination adrenaline-vasopressin was ranked only tenth. This suggests that the two most widely used and investigated vasopressors or combination of vasopressors may not necessarily be the most effective in terms of potential impact on survival.
Interestingly, adrenaline (a potent β-and α-adrenergic agonist) was ranked below noradrenaline (which has higher affinity for α-adrenergic receptors than for β-receptors) and phenylephrine (a pure α-adrenergic agonist). Currently, several nonrandomized studies have questioned the benefit of adrenaline administration during CPR with worse neurologic outcome in patients receiving adrenaline, even in the face of an increased ROSC (11, (75) (76) (77) (78) . This has been explained by some authors with a detrimental effect of β-adrenergic stimulation on postresuscitation myocardial function and cerebral perfusion during CPR (79) (80) (81) . However, other studies did not confirm these findings (82, 83) , and a small study showed increased cerebral oxygenation following adrenaline administration (84) . In our study, we found no evidence of worse outcome associated with either high-or low-dose adrenaline. However, it should be noted that most of the studies compared adrenaline with another vasopressor, and use of open-label, low-dose adrenaline was generally allowed at some point of CPR algorithm in most of the studies. An ongoing randomized trial will hopefully provide a definitive answer on the role of prehospital adrenaline administration (Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of drug administration in Cardiac arrest [PARAMEDIC-2]: [ISRCTN73485024]) (85) .
Nevertheless, in absence of adequately powered and high-quality RCTs, we believe that clinicians should follow current international guidelines provided by professional societies (10, 86) , although application of the adrenaline-vasopressin-methylprednisolone protocol might be considered in the ICU setting. External validity and reproducibility of positive results obtained by Mentzelopoulos et al (16) and feasibility of their protocol outside the ICU should be confirmed in additional pragmatic international mRCTs, before widespread use could be recommended (87, 88) .
A strength of our study is that we systematically searched and included only RCTs performed on this topic. In contrast to previous reviews and meta-analyses, our network metaanalytic statistical approach allowed us to indirectly compare all the vasopressors used in RCT among each other.
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Our study has some limitations. First, we included studies performed in both OHCA and IHCA settings. However, we performed specific subgroup analyses for the different settings showing that the positive results of a combined treatment of vasopressin, adrenaline, and methylprednisolone arise from two studies performed by Mentzelopoulos et al in IHCA. Second, the quality of included trials was heterogeneous, with the majority of trials carrying an unclear or a high risk of bias. Our analysis focusing on ROSC highlighted a high heterogeneity between studies, which limits the validity of this specific analysis. We hypothesize that heterogeneity is most likely due to case mix, ancillary treatments, and possibly different ROSC definitions. However, we believe that this secondary analysis provides interesting clues to support future investigations on the most effective treatments. The definition of good neurologic outcome is not consistent across all included studies, although all but two define good neurologic outcome as Cerebral Performance Category score 1 or 2, in line with current recommendations (89) . Finally, all limitations of meta-analyses apply also to network meta-analyses (20, 23, 90) . In particular, meta-analyses should be considered hypothesis generating, particularly when available trials are heterogeneous or with high risk of bias.
CONCLUSIONS
This NMA of RCTs found that only a combined treatment with adrenaline, vasopressin, and methylprednisolone was associated with improved survival with a good neurologic outcome and ROSC probability compared with several other comparators, including adrenaline, particularly in IHCA. No significant randomized evidences support neither discourage the use of adrenaline during cardiac arrest. High-quality studies are needed to confirm these findings and explore further therapeutic treatments in this setting.
